<DOC>
	<DOCNO>NCT00800579</DOCNO>
	<brief_summary>The purpose study evaluate safety tolerability escalate dos GS-9411 healthy male volunteer . GS-9411 sodium channel inhibitor , may restore airway hydration mucociliary clearance lung .</brief_summary>
	<brief_title>Trial Assess Safety , Tolerability Pharmacokinetics GS-9411 Healthy Male Volunteers</brief_title>
	<detailed_description>GS-9411 evaluate potential therapy improve airway hydration mucociliary clearance patient cystic fibrosis . This study evaluate safety tolerability 3 dose level GS-9411 inhale product , compare match placebo .</detailed_description>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Cystic Fibrosis</mesh_term>
	<criteria>Males 18 45 year age . No clinically important abnormal physical finding screen . No clinically relevant abnormal lab result screen . Normal ( abnormal clinically significant ) ECG . Normal ( abnormal clinically significant ) blood pressure ( BP ) heart rate ( HR ) . Body weight 70 125 kg body mass index ( BMI ) 18 28 kg/m2 , outside range , clinically significant agree sponsor principal investigator . Able communicate well investigator comply requirement entire study . Provision write informed consent . Nonsmokers least 6 month duration ( &lt; 10 pack year history ) prior study entry . Negative drug abuse ( include alcohol ) Screening Day 5 . Must willing abstain alcohol strenuous exercise 48hour period prior admission confine clinic . Forced expiratory volume 1 second ( FEV1 ) great equal 80 % predict normal age , gender , height per Hankinson et al1 Screening Predose . Normal intraocular pressure 10 22 mmHg . Male subject sexually active must willing use effective barrier contraception ( e.g. , condom ) heterosexual intercourse Baseline/Day 0 completion study continue least 30 day date last dose study drug . Male subject must refrain sperm donation Day 1 completion study continue least 30 day date last dose study drug . Administration investigational drug period 0 12 week entry study . A need medication period 0 5 day entry study , except deem principal investigator/clinical investigator interfere outcome study . Existence surgical medical condition , judgment clinical investigator , might interfere absorption , distribution , metabolism , excretion drug . Presence history allergy require treatment . Hay fever allow unless active require treatment within previous 2 month . Donation loss great 400 mL blood period 0 12 week entry study . Serious adverse reaction hypersensitivity drug . Presence history pulmonary disease ( e.g. , asthma , emphysema , chronic bronchitis , cystic fibrosis , bronchiectasis ) . Consumption drug and/or herbal preparation capable induce hepatic enzyme metabolism ( e.g. , barbiturate , rifampicin , carbamazepine , phenytoin , primidone , St. John 's Wort ) enzymeinhibiting agent ( e.g. , cimetidine ) similar drug within 30 day ( 5 halflives inducing/inhibiting agent , whichever long ) enrollment study . Major surgery within 6 month start study . Subjects experience significant upper low respiratory tract infection within 6 week prior admission . Subjects significant history respiratory , renal , hepatic , cardiovascular ( include history systemic hypertension require therapy ) , metabolic , neurological , hematological , gastrointestinal , cerebrovascular , significant medical illness disorder , judgment investigator , may interfere study require treatment may affect evaluation efficacy safety study drug . Subjects elevate liver enzyme concentration . Haemoglobin level &lt; 130 g/L take Screening Predose . Plasma potassium &gt; 5 mEq/L take Screening Predose . Poor venous access . Intraocular pressure &gt; 21 mm Hg</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>October 2009</verification_date>
	<keyword>cystic fibrosis</keyword>
	<keyword>CF</keyword>
	<keyword>mucociliary clearance</keyword>
	<keyword>amiloride</keyword>
	<keyword>ENaC</keyword>
	<keyword>ENaC Inhibitor</keyword>
	<keyword>airway hydration</keyword>
	<keyword>epithelial sodium channel inhibitor</keyword>
</DOC>